CN102058538A - Cycloartenyl ferulate solid dispersion and preparation thereof - Google Patents
Cycloartenyl ferulate solid dispersion and preparation thereof Download PDFInfo
- Publication number
- CN102058538A CN102058538A CN2009102380911A CN200910238091A CN102058538A CN 102058538 A CN102058538 A CN 102058538A CN 2009102380911 A CN2009102380911 A CN 2009102380911A CN 200910238091 A CN200910238091 A CN 200910238091A CN 102058538 A CN102058538 A CN 102058538A
- Authority
- CN
- China
- Prior art keywords
- solid dispersion
- cycloartenyl ferulate
- ferulate
- cycloartenyl
- polyvidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QVZGAIWUSYVGBJ-UHFFFAOYSA-N Cycloartenyl ferulate Natural products CCC12CCC3(C)C(C(C)CCC=C(C)C)CCC3(C)C1CCC(C1(C)C)C2CCC1OC(=O)C=CC1=CC=C(O)C(OC)=C1 QVZGAIWUSYVGBJ-UHFFFAOYSA-N 0.000 title claims abstract description 111
- FODTZLFLDFKIQH-UHFFFAOYSA-N cycloartenol trans-ferulate Natural products C1=C(O)C(OC)=CC(C=CC(=O)OC2C(C3CCC4C5(C)CCC(C5(C)CCC54CC53CC2)C(C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-UHFFFAOYSA-N 0.000 title claims abstract description 111
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 title claims abstract description 111
- 239000007962 solid dispersion Substances 0.000 title claims abstract description 83
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 20
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 21
- 229920003081 Povidone K 30 Polymers 0.000 claims description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- 239000003826 tablet Substances 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 150000005846 sugar alcohols Polymers 0.000 claims description 5
- 239000006196 drop Substances 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 229960000502 poloxamer Drugs 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 229920002675 Polyoxyl Polymers 0.000 claims description 2
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 229940101027 polysorbate 40 Drugs 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 abstract description 22
- 239000012876 carrier material Substances 0.000 abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 239000003814 drug Substances 0.000 description 11
- 238000001035 drying Methods 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 229960004756 ethanol Drugs 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 238000001694 spray drying Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- -1 ferulic acid ester Chemical class 0.000 description 5
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229940114124 ferulic acid Drugs 0.000 description 3
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 3
- 235000001785 ferulic acid Nutrition 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 3
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 244000025352 Artocarpus heterophyllus Species 0.000 description 2
- 235000008725 Artocarpus heterophyllus Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical group O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 210000002451 diencephalon Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses cycloartenyl ferulate solid dispersion, which comprises cycloartenyl ferulate and povidone serving as a carrier material. The invention further discloses a medicinal preparation and a preparation method of the solid dispersion. Experiments prove that the solid dispersion makes obvious technical progress in technical indexes such as dissolution rate, stability, water solubility, bioavailability and the like.
Description
Technical field
The invention discloses a kind of solid dispersion of cycloartenyl ferulate, comprise cycloartenyl ferulate and, belong to field of medicaments as the polyvidone of carrier.
Background technology
Oryzanol is a kind of natural mixture of being formed based on the ferulic acid ester of the ferulic acid ester of ring jackfruit alcohols and sterols, and outward appearance is white or light yellow crystal powder.In the Testa oryzae oil oryzanol, ring jackfruit alcohols ferulic acid ester content is about 70-80%.The discovery that studies for a long period of time, oryzanol has multiple pharmacologically active, comprising: the absorption of blood fat reducing, cholesterol reducing, prevent lipid oxidation, angiocardiopathy preventing.In addition, research in recent years finds that also oryzanol can relax various health obstacles and the vegetative dystonie phenomenon of women after entering into the climacteric period, and improves the diencephalon functional disorder.
Oryzanol is soluble in chloroform, the acetone and other organic solvent, is difficult to water-solublely, and oral availability is very low, and a large amount of medicine of needs brings side effect and economic loss when causing that the patient is actual to take.In the prior art, the oryzanol preparation of Ying Yonging is an injection clinically, need inject at deep part of muscle during use, uses inconvenience, and intramuscular injection is simultaneously lumpd easily, brings big painful to patient.
In the prior art, had disclosedly at the solubilization studies of oryzanol raw material, all disclose oryzanol vegetable oil solubility preparation as Chinese patent CN123428, CN2007100156403 etc., improved bioavailability, clinical effectiveness is better than general tablet.But because must intramuscular injection during oily solubility preparation clinical practice, patient's pain sensation is more intense, and easily causes the muscle caking.Oily solubility preparation onset simultaneously is slow, needs about one month time remaining to carry out intramuscular injection, and this can have a strong impact on patient's live and work.Chinese patent application CN2004100945568, CN100386082C etc. disclose surface active ingredients such as oryzanol and phospholipid are combined and have been prepared into the scheme of liposome, Emulsion etc.These technical schemes depend on surface active ingredient used in the scheme in fact to the raising of oryzanol dissolubility, when having improved the oryzanol dissolubility, also brought the side effect of surfactant itself, and injection is convenient not as oral formulations in clinical practice.
Existing oral formulations as 200410012115.9 capsules that disclose oryzanol, wherein also contains the oiliness composition; 200610012341.6 disclose a kind of dispersible tablet, but it can not significantly improve the dissolution and the bioavailability of insoluble drug.Still unexposed in the prior art have an obvious oral formulations that improves the oryzanol dissolution.
Cycloartenyl ferulate is one of main component in the oryzanol.Compare with the oryzanol raw material, cycloartenyl ferulate monomer dissolubility is lower, and bioavailability is poorer.Still there is not research to relate to stripping and the biological utilisation problem of improving cycloartenyl ferulate in the prior art.It also is unforeseen that the solubilising scheme that will be used for the oryzanol raw material is used for the cycloartenyl ferulate effect.
Summary of the invention
It is a kind of technological means that solves dissolution and drug bioavailability that insoluble drug is made solid dispersion.In solid dispersion, the insoluble drug molecule is distributed in the high-molecular weight carrier material with amorphous form.At different medicines, need screen the solid dispersion carrier material.Solid dispersion carrier material commonly used in the prior art comprises that cellulose, microcrystalline Cellulose, beta-schardinger dextrin-, alpha-cyclodextrin, Polyethylene Glycol etc. are multiple.
In inventor's early-stage Study, obtained cycloartenyl ferulate by effectively the component in the oryzanol being separated, the research is open in the patent 200810114405.2 of applicant's earlier application, and this full patent texts can be used as the application's reference.After obtaining cycloartenyl ferulate the applicant to find that above-mentioned these carrier materials are used to prepare the effect that its dissolution of cycloartenyl ferulate solid dispersion improves unsatisfactory.
The applicant is through lot of experiments, surprisingly find, select for use polyvidone as carrier material at cycloartenyl ferulate, with select other solid dispersion carrier material for use and compare, prepared cycloartenyl ferulate solid dispersion has the effect unexpected, that dissolution significantly improves, and resulting solid dispersion good stability, bioavailability height.
Based on above-mentioned discovery, the invention provides the cycloartenyl ferulate solid dispersion that a kind of stable, dissolution and bioavailability significantly improve, comprise cycloartenyl ferulate and as the polyvidone of solid dispersion carrier material, the present invention also further provides and has contained the pharmaceutical preparation that above solid dispersion and other pharmacy can be accepted adjuvant.Simultaneously, the present invention also provides the said medicine corresponding preparation method.
Among the present invention, described polyvidone can disperse cycloartenyl ferulate to make it to be dissolved in water or other solvent, preferred polyvidone mean molecule quantity is 5000D-50000D, more preferably the mixture of one or more in 30 POVIDONE K 30 BP/USP 15,30 POVIDONE K 30 BP/USP 30, the 30 POVIDONE K 30 BP/USP 90.
Among the present invention, cycloartenyl ferulate can be from the oryzanol raw material purification, also can be to adopt the chemical industry method synthetic.
In the present invention, the mass ratio of polyvidone and cycloartenyl ferulate is 1: 100-100: 1, be preferably 2: 1-40: and 1, most preferred is 4: 1-20: 1.
Among the present invention, in order further to improve the dissolution of cycloartenyl ferulate, can add synergist, suitable synergist can be:
Poloxamer in polyoxyethylene-polyoxypropylene copolymer, preferred poloxamer 188;
Vitamin and derivant thereof, preferred vitamin E, vitamin E polyethylene glycol succinic acid ester;
Lecithin comprises egg yolk lecithin, soybean phospholipid, preferably soya lecithin;
Polyalcohols comprises organic polyhydric alcohol liquid under the room temperature, preferred propylene glycol, glycerol, ethylene glycol or its mixture;
Tweens, preferred polysorbate40, polysorbate60, Tween 80, most preferably Tween 80;
Polyoxyl stearate, preferred polyoxyethylene stearate (40) ester;
Preferably, the synergist that is used for solid dispersion of the present invention is polyhydric alcohol and tween.
In containing the cycloartenyl ferulate solid dispersion of synergist, the mass ratio of cycloartenyl ferulate, polyvidone, synergist is 1: 2-20: 0.2-5.
On the other hand, the present invention also provides the preparation method of cycloartenyl ferulate solid dispersion.
Solid dispersion of the present invention can adopt following method preparation:
Cycloartenyl ferulate, polyvidone are dissolved in the organic solvent, thereby organic solvent is reclaimed and the dry cycloartenyl ferulate solid dispersion that obtains.Wherein, used organic solvent can be any Organic substance that can dissolve cycloartenyl ferulate, polyvidone, for example alcohol, acetonitrile, oxolane, dichloromethane, chloroform, ethyl acetate, acetone or its any mixture.The actual needs of bound drug safety and preparation, the preparation method of the present invention preferably organic solvent of usefulness are alcohol, ethyl acetate, acetone and/or its mixture.When using alcohol as organic solvent, the present invention preferably uses dehydrated alcohol, absolute methanol, ethanol water, methanol aqueous solution.In the above-mentioned course of dissolution, can heat in order to accelerate dissolution velocity, the temperature of heating is at 30-85 ℃.
Solid dispersion of the present invention is not limited to only adopt method for preparing, and other method such as fusion method, fusion-solvent methods etc. that are used to prepare solid dispersion all can adopt suitable preparation parameter to be used to prepare solid dispersion of the present invention.
In above-mentioned preparation method, the drying means that is adopted is unrestricted, and industrial drying means commonly used such as drying under reduced pressure, spray drying, constant pressure and dry all can be used for preparation method of the present invention.For example, the distillation of gained solution decompression can be obtained the coprecipitate of paste, be dried pulverizing; Can directly collect the dried powder of solid dispersion with gained solution by the spray drying machine; Can then gained paste precipitate be pulverized at heating, drying organic solvent under the normal pressure and get final product.
Solid dispersion of the present invention can enter human body by suitable route of administration, normally oral or parenteral route.Use in order to carry out this class, solid dispersion of the present invention can be prepared as acceptable any dosage form on the pharmaceutics by adding suitable pharmaceutic adjuvant.When being used for the treatment of, can be directly give with the simple cycloartenyl ferulate solid dispersion powder of patient or directly the fill capsulae vacuus is oral as active component.During cycloartenyl ferulate solid dispersion practical application usually of the present invention all is to occur with the medicine type that contains pharmaceutic adjuvant, therefore the invention provides the preparation of cycloartenyl ferulate solid dispersion.
But by suitable oral, the non-intestinal that is mixed with pharmaceutic adjuvant, the dosage form of topical can be tablet, capsule, pill, granule, suspensoid, powder, oral liquid, injectable or infusion solution or suspensoid, suppository etc., preferred in actual applications dosage form is a peroral dosage form, is easy to the patient and uses.
Solid dispersion of the present invention can combine with adjuvant and be prepared into various peroral dosage forms, as tablet, capsule, granule, drop pill etc., the method of used preparation can be the conventional method of drug world, tablet for example can be made mixture tabletting system then by add suitable additive to cycloartenyl ferulate solid dispersion of the present invention; Capsule can add in the capsule shells by the granule that is processed into powder or specific standard to cycloartenyl ferulate solid dispersion adding pharmaceutic adjuvant of the present invention and make.Preferred dosage form is tablet and capsule, and these dosage forms can adopt routine techniques and conventional machine to prepare.
According to the difference of pharmaceutical dosage form, can randomly contain other suitable pharmaceutic adjuvant.Adaptable pharmaceutically common adjuvant includes but not limited to:
One or more pharmaceutically useful filleies include but not limited to sucrose, lactose, microcrystalline Cellulose, starch etc.;
One or more disintegrating agents include but not limited to polyvinylpolypyrrolidone, carboxymethyl starch sodium, cross-linking sodium carboxymethyl cellulose;
One or more lubricants include but not limited to magnesium stearate, colloidal silica;
The adjuvant (flavoring agent, coloring agent) that one or more are used to improve abnormal smells from the patient, impression includes but not limited to Herba Menthae, essence, beta-carotene;
One or more stabilizing agents, antioxidant include but not limited to butylated hydroxytoluene, alpha-tocopherol, propyl gallate, malonic acid, vitamin C, sodium sulfite, sodium sulfite, sodium pyrosulfite.
As required, can also add other suitable adjuvant in the preparation process.
In foregoing, described filler, disintegrating agent, lubricant, coloring agent, flavoring agent etc. belong to the pharmaceutics category, are that those skilled in the art are familiar with or should be familiar with.Used " the including but not limited to " of applicant be meant and comprise in the described concrete material one or several, but also can be well known to those skilled in the art, the material that plays the same purpose effect outside described.For example said disintegrating agent is except that polyvinylpolypyrrolidone, carboxymethyl starch sodium, cross-linking sodium carboxymethyl cellulose, and those skilled in the art will be appreciated that as carboxymethylcellulose calcium, low-substituted hydroxypropyl cellulose and also can be used as disintegrating agent.
It will be appreciated by those skilled in the art that the process that the resulting solid dispersion preparation of the present invention is adopted is that pharmaceutical field is common.For example, knowledge according to galenic pharmacy, cycloartenyl ferulate solid dispersion of the present invention and its pharmaceutic adjuvant be dissolved in stir in the systems such as alcohol, aqueous solution or fully grind after go out to desolvate and dry, thereby obtain the dry suspension or the powder of solid dispersion of the present invention, further then tabletting or encapsulated.This preparation technique is that the present technique field is known, and the technical scheme that those skilled in the art adopt on formulation method does not influence protection scope of the present invention.Specifically be prepared into any dosage form and adopt which type of preparation process according to concrete production requirement decision.
Cycloartenyl ferulate solid dispersion and preparation thereof that the present invention is obtained carry out dissolution in vitro test, accelerated stability test and solubility experiment, the result shows that the cycloartenyl ferulate solid dispersion that the present invention openly prepares can make cycloartenyl ferulate reach very high dispersity in polyvidone, improve the dissolution in vitro of cycloartenyl ferulate greatly, thereby improved its bioavailability.
The specific embodiment
Embodiment 1
With 4g cycloartenyl ferulate, 15g 30 POVIDONE K 30 BP/USP 30, mixed grinding 20min, the gained abrasive flour joined in the 80ml ethanol stir 10min, gained solution is poured Rotary Evaporators into, take out in baking oven dry when being concentrated into 10ml, the gained solid was pulverized 80 mesh sieves, promptly got cycloartenyl ferulate solid dispersion of the present invention.
Embodiment 2
Measure the 150ml ethyl acetate, add fully vibration dissolving of 7g 30 POVIDONE K 30 BP/USP 90 therein.Add cycloartenyl ferulate 1g then, about 15 minutes of 70 ℃ of following heated and stirred, gained solution is poured Rotary Evaporators into, takes out in baking oven dry when being concentrated into 20ml, the gained solid was pulverized 80 mesh sieves, promptly got cycloartenyl ferulate solid dispersion of the present invention.
Embodiment 3
Measure 50ml ethanol, add 20g 30 POVIDONE K 30 BP/USP 30,1g propylene glycol, 1g cycloartenyl ferulate, 0.2g egg yolk lecithin therein, the abundant stirring and dissolving of heating in 50 ℃ of water-baths.Gained solution is poured Rotary Evaporators into, takes out drying in baking oven when being concentrated into 15ml, and the gained solid was pulverized 80 mesh sieves, promptly got cycloartenyl ferulate solid dispersion of the present invention.
Embodiment 4
10g cycloartenyl ferulate, 100g 30 POVIDONE K 30 BP/USP 90,5g glycerol are dissolved in 99% ethanol, again solution is made the cycloartenyl ferulate solid dispersion with the spray drying device spray drying, further drying is 2 hours under 60 ℃, remove residual solvent, gained powder art is cycloartenyl ferulate solid dispersion of the present invention.
Embodiment 5
Cycloartenyl ferulate 5g, 30 POVIDONE K 30 BP/USP 15 15g are dissolved in the acetone, again solution are made the cycloartenyl ferulate solid dispersion with the spray drying device spray drying, 60 ℃ were descended further dry 2 hours, and removed residual solvent.
Embodiment 6
Measure the ethanol of 100ml 95%, adding propylene glycol 2ml, 30 POVIDONE K 30 BP/USP 30 8g fully vibrate and dissolve back adding cycloartenyl ferulate 1.5g, about 10 minutes of 75 ℃ of following heated and stirred, gained solution is poured Rotary Evaporators into, take out in baking oven dry when being concentrated into 15ml, the gained solid was pulverized 80 mesh sieves, promptly got cycloartenyl ferulate solid dispersion of the present invention.
Embodiment 7
Measure the ethanol of 100ml 95%, add 3ml glycerol, 28g 30 POVIDONE K 30 BP/USP 15 and fully add the 4g cycloartenyl ferulate in vibration dissolving back, about 10 minutes of 80 ℃ of following heated and stirred, gained solution is poured Rotary Evaporators into, take out in baking oven dry when being concentrated into 18ml, the gained solid was pulverized 80 mesh sieves, promptly got cycloartenyl ferulate solid dispersion of the present invention.
Embodiment 8
Measure the ethanol of 200ml 95%, add 3ml Tween 80,30g 30 POVIDONE K 30 BP/USP 32 and fully add the 5g cycloartenyl ferulate in vibration dissolving back, about 20 minutes of 70 ℃ of following heated and stirred, gained solution is poured Rotary Evaporators into, take out in baking oven dry when being concentrated into 15ml, the gained solid was pulverized 80 mesh sieves, promptly got cycloartenyl ferulate solid dispersion of the present invention.
Embodiment 9
Get the ethanol of 100ml 95%, add fully vibration dissolving adding 5g cycloartenyl ferulate of 2ml polysorbate60,20g 30 POVIDONE K 30 BP/USP 15, about 10 minutes of 80 ℃ of following heated and stirred, gained solution is poured Rotary Evaporators into, take out in baking oven dry when being concentrated into the 15ml left and right sides, the gained solid was pulverized 80 mesh sieves, promptly got cycloartenyl ferulate solid dispersion of the present invention.
Embodiment 10
Measure the ethanol of 100ml 95%, add 5ml propylene glycol, 50g 30 POVIDONE K 30 BP/USP 15 and fully add the 6g cycloartenyl ferulate in vibration dissolving back, about 10 minutes of 80 ℃ of following heated and stirred, gained solution is poured Rotary Evaporators into, take out in baking oven dry when being concentrated into the 15ml left and right sides, the gained solid was pulverized 80 mesh sieves, promptly got cycloartenyl ferulate solid dispersion of the present invention.
Embodiment 11
It is standby that the cycloartenyl ferulate solid dispersion of embodiment 6, microcrystalline Cellulose, polyvinylpolypyrrolidone, magnesium stearate are crossed 80 mesh sieves respectively.Take by weighing cycloartenyl ferulate solid dispersion, microcrystalline Cellulose, polyvinylpolypyrrolidone, magnesium stearate mix homogeneously according to above table, tabletting promptly gets tablet of the present invention, totally 100.
Embodiment 12
With the cycloartenyl ferulate solid dispersion and the starch uniform mixing of the embodiment of the invention 8, add an amount of granulation of 5% starch slurry, drying again, add the magnesium stearate mixing, then gained is joined in the capsule totally 200.
Embodiment 13
With the cycloartenyl ferulate solid dispersion of the embodiment of the invention 4 and microcrystalline Cellulose, lactose uniform mixing, granulate with dehydrated alcohol, drying adds the magnesium stearate mixing then, the direct bag distribution packaging of granule, totally 130 bags.
Embodiment 14
The cycloartenyl ferulate solid dispersion of the embodiment of the invention 10 is mixed with cetomacrogol 1000, be heated to 80 ℃, mix up the drop pill machine, it is splashed in the dimethylsilane, promptly get cycloartenyl ferulate solid dispersion drop pill of the present invention, totally 30.
Embodiment 15
It is standby that the cycloartenyl ferulate solid dispersion of embodiment 6, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, magnesium stearate are crossed 80 mesh sieves respectively.Take by weighing cycloartenyl ferulate solid dispersion, microcrystalline Cellulose, polyvinylpolypyrrolidone, magnesium stearate mix homogeneously according to above table, tabletting promptly gets tablet of the present invention, totally 500.
The comparative example 1
Measure the 150ml ethyl acetate, fully vibrate it is dissolved fully to wherein adding the 7g microcrystalline Cellulose.Adding 1g cycloartenyl ferulate, extremely dissolving was abundant in about 15 minutes for 70 ℃ of following heated and stirred, and gained solution is poured Rotary Evaporators into, takes out drying in baking oven when adopting distilling under reduced pressure to be concentrated into 20ml, dry gained solid is pulverized 80 mesh sieves, promptly.
The comparative example 2
Measure the 150ml ethyl acetate, it is dissolved fully to wherein adding the 188 abundant vibrations of 7g poloxamer.Adding 1g cycloartenyl ferulate, extremely dissolving was abundant in about 15 minutes for 60 ℃ of following heated and stirred, and gained solution is poured Rotary Evaporators into, takes out drying in baking oven when adopting distilling under reduced pressure to be concentrated into 20ml, dry gained solid is pulverized 80 mesh sieves, promptly.
The comparative example 3
Measure the 150ml ethyl acetate, fully vibrate it is dissolved fully to wherein adding the 7g polyethylene glycol 6000.Adding 1g cycloartenyl ferulate, extremely dissolving was abundant in about 20 minutes for 65 ℃ of following heated and stirred, and gained solution is poured Rotary Evaporators into, takes out drying in baking oven when adopting distilling under reduced pressure to be concentrated into 20ml, dry gained solid is pulverized 80 mesh sieves, promptly.
The comparative example 4
With 1g cycloartenyl ferulate, 7g 30 POVIDONE K 30 BP/USP 30, mix and stir, cycloartenyl ferulate polyvidone common mixt.
Experimental example 1 accelerated stability test
Place 40 ℃, the calorstat of 75% relative humidity to preserve six months in the solid dispersion of the embodiment of the invention 6,11 preparation and tablet thereof, respectively 0 month, January, February, March, June its dissolution of sampling and measuring and content.
High-efficient liquid phase chromatogram condition: with octadecylsilane chemically bonded silica is filler; Mobile phase A is methanol-oxolane (10: 23), and Mobile phase B is acetonitrile-water (55: 15), and flow velocity is 1.0ml/min, gradient elution; Column temperature is 45 ℃; The detection wavelength is 325nm.
According to two appendix V of Chinese Pharmacopoeia version in 2005 D, get an amount of sample (being equivalent to contain cycloartenyl ferulate 10mg), the accurate title, decide, porphyrize is put in the 100ml measuring bottle, adds that mobile phase is ultrasonic to be made dissolving and be diluted to scale, shake up, filter, precision is measured filtrate 10 μ l and is injected chromatograph of liquid, the record chromatogram; Other gets cycloartenyl ferulate reference substance 10mg, and accurate the title decides, and puts in the 100ml measuring bottle, adds the dissolving of mobile phase A liquid and is diluted to scale.By the content of external standard method with the calculated by peak area cycloartenyl ferulate.
According to 2005 editions two appendix XC second subtraction units of Chinese Pharmacopoeia, be solvent with water 500ml, precision takes by weighing an amount of sample (being equivalent to contain cycloartenyl ferulate 10mg).Take a sample when operating in 45min, with its dissolution of high effective liquid chromatography for measuring in accordance with the law.
The gained data are following table
Table 1 solid dispersion stability of the present invention and dissolution are investigated
As can be seen from Table 1, solid dispersion of the present invention and tablet thereof are under the accelerated test condition, and dissolution and content do not have to change substantially, have illustrated that cycloartenyl ferulate solid dispersion of the present invention and tablet stability thereof are good.
Experimental example 2 solubility tests test
Solid dispersion of the present invention has not only improved the dissolution of cycloartenyl ferulate greatly, has also improved its water solublity.
Get an amount of cycloartenyl ferulate solid dispersion, make it to form saturated solution in right amount with purified water, filter with the 0.45um filter membrane, dilution back is with spectrophotometric determination 320 place's traps, by the absorptance (ECM 1%) of cycloartenyl ferulate thus be the dissolubility that the concentration of 250 calculating saturated solutions obtain cycloartenyl ferulate in the cycloartenyl ferulate solid dispersion.
At normal temperatures and pressures, the dissolubility of cycloartenyl ferulate in water is less than 1mg/ml.
Cycloartenyl ferulate solid dispersion of the present invention is at cycloartenyl ferulate: the dissolubility of cycloartenyl ferulate is greater than 5mg/ml during 30 POVIDONE K 30 BP/USP 30 (1: 2).
Cycloartenyl ferulate solid dispersion of the present invention is at cycloartenyl ferulate: the dissolubility of cycloartenyl ferulate is greater than 6mg/ml during 30 POVIDONE K 30 BP/USP 30 (1: 3).
Cycloartenyl ferulate solid dispersion of the present invention is at cycloartenyl ferulate: the dissolubility of cycloartenyl ferulate is greater than 8mg/ml during 30 POVIDONE K 30 BP/USP 30 (1: 5).
By above-mentioned data as seen, cycloartenyl ferulate solid dispersion of the present invention has remarkable effect to improving the cycloartenyl ferulate dissolubility.
Experimental example 4 different carriers materials, preparation method dissolution contrast test
According to 2005 editions two appendix XC second subtraction units of Chinese Pharmacopoeia, be solvent with water 500ml, precision takes by weighing an amount of sample (being equivalent to contain cycloartenyl ferulate 10mg).Take a sample when operating in 45min, with its dissolution of high effective liquid chromatography for measuring in accordance with the law.
High-efficient liquid phase chromatogram condition: with octadecylsilane chemically bonded silica is filler; Mobile phase A is methanol-oxolane (10: 23), and Mobile phase B is acetonitrile-water (55: 15), and flow velocity is 1.0ml/min, gradient elution; Column temperature is 45 ℃; The detection wavelength is 325nm.
Measure embodiment 2, comparative example 1, comparative example 2, comparative example 3, comparative example 4 dissolution at room temperature respectively, be labeled as sample 1, sample 2, sample 3, sample 4, sample 5 respectively.
| Sample number | 45min dissolution (%) |
| Sample 1 | 91.2 |
| Sample 2 | 37.3 |
| Sample 3 | 39.5 |
| Sample 4 | 41.7 |
| Sample 5 | 1.4 |
By above-mentioned data as seen, compare, use the dissolution that polyvidone can very significantly improve cycloartenyl ferulate with other carrier materials commonly used of solid dispersion.
The mensuration of experimental example 5 bioavailability
Get the tablet of the embodiment of the invention 11 preparations.
Get 10 mices, give tablet of the present invention, every dosage 10mg.
Under no feed situation, put into the oral cavity of mice with the dosage of 10mg, it is swallowed.Make with extra care purified water 20ml.Before administration, after the administration 0,0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h, 24h, 48h, 72h draws blood respectively and measure cycloartenyl ferulate content in the blood.
Testing result shows that solid dispersion tablet bioavailability of the present invention is good, is 60%.
Claims (16)
1. cycloartenyl ferulate solid dispersion comprises cycloartenyl ferulate and as the polyvidone of solid dispersion carrier.
2. according to the cycloartenyl ferulate solid dispersion of claim 1, described polyvidone molecular weight is 5000D～50000D.
3. according to the solid dispersion of claim 2, described polyvidone is 30 POVIDONE K 30 BP/USP 15,30 POVIDONE K 30 BP/USP 30,30 POVIDONE K 30 BP/USP 90 or its mixture.
4. according to the cycloartenyl ferulate solid dispersion of claim 1, the mass ratio of polyvidone and cycloartenyl ferulate is 2: 1～20: 1.
5. according to the cycloartenyl ferulate solid dispersion of claim 3, the mass ratio of polyvidone and cycloartenyl ferulate is 4: 1～10: 1.
6. according to the cycloartenyl ferulate solid dispersion of above-mentioned arbitrary claim, also comprise synergist, described synergist is selected from one or more the mixture in polyhydric alcohol, poloxamer, vitamin E, lecithin, polyoxyl stearate, the tween.
7. according to the cycloartenyl ferulate solid dispersion of claim 6, the mass ratio of cycloartenyl ferulate, polyvidone, synergist is 1: 2～20: 0.2～5.
8. according to the cycloartenyl ferulate solid dispersion of claim 6, described polyhydric alcohol is one or more the mixture in ethylene glycol, propylene glycol, the glycerol.
9. according to the cycloartenyl ferulate solid dispersion of claim 6, described tween is one or more the mixture in polysorbate40, polysorbate60, the Tween 80.
10. a method for preparing the cycloartenyl ferulate solid dispersion of above-mentioned arbitrary claim comprises cycloartenyl ferulate, polyvidone are dissolved in the organic solvent, reclaims organic solvent and exsiccant step.
11. according to the method for claim 10, described organic solvent is selected from one or more the mixture in alcohol, ethyl acetate, the acetone.
12. according to the method for claim 11, described alcohol is ethanol or ethanol water.
13. according to the method for claim 11, described alcohol is methanol or methanol aqueous solution.
14. a pharmaceutical preparation contains the cycloartenyl ferulate solid dispersion of claim 1.
15. according to the preparation of claim 14, it is an oral formulations.
16. according to the preparation of claim 15, described peroral dosage form is capsule, tablet, granule, powder or drop pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102380911A CN102058538B (en) | 2009-11-18 | 2009-11-18 | Cycloartenyl ferulate solid dispersion and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102380911A CN102058538B (en) | 2009-11-18 | 2009-11-18 | Cycloartenyl ferulate solid dispersion and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102058538A true CN102058538A (en) | 2011-05-18 |
| CN102058538B CN102058538B (en) | 2012-08-22 |
Family
ID=43994167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102380911A Expired - Fee Related CN102058538B (en) | 2009-11-18 | 2009-11-18 | Cycloartenyl ferulate solid dispersion and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102058538B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102125566A (en) * | 2011-01-11 | 2011-07-20 | 北京世纪博康医药科技有限公司 | Pharmaceutical composition comprising cycloartenyl ferulate |
| CN102755334A (en) * | 2011-01-11 | 2012-10-31 | 北京世纪博康医药科技有限公司 | Medicine composition of cycloartenyl ferulate |
| CN111529494A (en) * | 2020-06-28 | 2020-08-14 | 江西谷物源食品有限公司 | Oryzanol micelle compound solid dispersion and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100411631C (en) * | 2006-10-27 | 2008-08-20 | 南方医科大学珠江医院 | Orally administered compound antihyperlipidemic |
| CN101480402B (en) * | 2008-12-17 | 2012-05-23 | 北京世纪博康医药科技有限公司 | Cycloartenyl ferulate composition and method for preparing the same |
-
2009
- 2009-11-18 CN CN2009102380911A patent/CN102058538B/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102125566A (en) * | 2011-01-11 | 2011-07-20 | 北京世纪博康医药科技有限公司 | Pharmaceutical composition comprising cycloartenyl ferulate |
| CN102755334A (en) * | 2011-01-11 | 2012-10-31 | 北京世纪博康医药科技有限公司 | Medicine composition of cycloartenyl ferulate |
| CN102125566B (en) * | 2011-01-11 | 2013-05-22 | 北京世纪博康医药科技有限公司 | Pharmaceutical composition comprising cycloartenyl ferulate |
| CN111529494A (en) * | 2020-06-28 | 2020-08-14 | 江西谷物源食品有限公司 | Oryzanol micelle compound solid dispersion and preparation method thereof |
| CN111529494B (en) * | 2020-06-28 | 2021-04-09 | 江西谷物源食品有限公司 | Oryzanol micelle compound solid dispersion and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102058538B (en) | 2012-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100342942B1 (en) | Oral micro-emulsion composition comprising Carduus marianus extract or silybin isolated therefrom | |
| CN100367930C (en) | Spontaneously dispersible N-benzoyl staurosporine compositions | |
| CN101088524B (en) | Phosphatide composition of active skull cap components and prepn. process and prepn. thereof | |
| CN102048688B (en) | Taxol submicroemulsion taking cholesterol complex as intermediate carrier | |
| JP2022530752A (en) | Self-emulsifying compositions of flavonoid polyphenols, their preparation methods, pharmaceutical compositions and uses | |
| CN110742861A (en) | Cannabidiol self-emulsifying drug delivery system, solid self-emulsifying preparation and preparation method thereof | |
| CN1543359A (en) | Compositions and preparation methods for bioavailable oral aceclofenac dosage forms | |
| CN102058537B (en) | Oryzanol solid dispersion composition and preparation thereof | |
| CN100463669C (en) | Self-emulsifying agent of compound artemether | |
| CN102058538B (en) | Cycloartenyl ferulate solid dispersion and preparation thereof | |
| CN102058515B (en) | Solid dispersion of 24-methylene cycloartanol ferulic acid eater and preparation thereof | |
| CN102058516B (en) | Solid dispersion and preparation thereof | |
| CN101143142A (en) | Silybin supersaturated self-emulsion composition and preparation method thereof | |
| CN104856954A (en) | Chlorogenic acid micro-emulsion as well as preparation technology and application thereof | |
| CN103690482B (en) | Take phosphatide complexes as glycyrrhizic acid self-emulsifiable preparation concentrated solution and the preparation method of intermediate | |
| CN102068419A (en) | Curcumin composition | |
| CN1457776A (en) | Self emulsified soft capsule of ginkgo leaf extract and its preparing method | |
| JP2006509785A (en) | Oral microemulsion composition of biphenyldimethyldicarboxylic acid | |
| CN102058606B (en) | Oryzanol medicinal composition | |
| CN1935126A (en) | Artemether self-emulified capsule and its preparing method | |
| CN100515427C (en) | self emulsifying soft capsule of breviscapine and its preparation | |
| CN1799550B (en) | Highly efficient formulation of hepsera and preparation method thereof | |
| CN105616355A (en) | Solid dispersion of glycyrol and preparation of solid dispersion | |
| JP2973077B2 (en) | Vitamin E preparation composition | |
| CN101156929A (en) | Turmeric water-insoluble saponin liposome and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: Room 1203, building D, No. 606, ningliu Road, Changlu street, Jiangbei new district, Nanjing City, Jiangsu Province Patentee after: Nanjing century Bokang Pharmaceutical Technology Co.,Ltd. Address before: 100070 Beijing City, Fengtai District science and Technology Park of Fengtai Haiying Road No. 9, building 3 203 Jintang Patentee before: BEIJING CENTURY BIOCOM PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120822 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |